Rybelsus (Oral Semaglutide) in Children Under 12: What the Off-Label Evidence Actually Shows

FDA Approval Status and the Under-12 Gap

Rybelsus received FDA approval in September 2019. The current U.S. label, updated in January 2026, limits its glycemic-control and cardiovascular-risk indications to adults with type 2 diabetes and states that safety and effectiveness in children are unknown. [1]

Any Rybelsus prescription for a child is therefore off-label. The completed pediatric trial does not change the label unless and until results are reviewed and the FDA approves a pediatric indication. [1, 12]

What "Off-Label" Means Clinically

Off-label prescribing is common in pediatrics, but the American Academy of Pediatrics emphasizes that decisions should rely on the best available evidence and expected benefit for the individual child. [2] For Rybelsus under age 12, no published trial establishes efficacy, safety, pharmacokinetics, or a dose.

Why the Under-12 Group Is Distinct

Children under 12 are not simply smaller adults. Gastric emptying rates, intestinal absorptive surface area, and hepatic enzyme maturation all differ from adult physiology, affecting oral drug bioavailability. Oral semaglutide's absorption depends critically on co-administration with the absorption enhancer sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC). The interplay between SNAC-mediated absorption and pediatric gastric physiology has not been characterized in any published study. [3]

Why Youth-Onset Type 2 Diabetes Makes This Question Urgent

Youth-onset type 2 diabetes is not rare or mild. The TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) trial (N=699, ages 10-17) found that glycemic control deteriorated faster in youth than in adult-onset disease, with a 52% rate of treatment failure on metformin at 3.86 years of follow-up. [4] Beta-cell function declined at roughly twice the rate seen in adult-onset type 2 diabetes. [4]

The Metformin Ceiling

Metformin remains an important initial option for metabolically stable youth with type 2 diabetes, but TODAY demonstrated its limitations clearly. When metformin monotherapy failed, adding rosiglitazone or intensive lifestyle intervention improved outcomes only modestly. No GLP-1 receptor agonist was part of the original TODAY protocol. The ADA's 2026 guidance now recommends considering a GLP-1 receptor agonist and/or SGLT2 inhibitor that is approved for the patient's pediatric age when goals are not met with metformin, with or without basal insulin. Rybelsus is not one of those pediatric-approved products. [5]

Obesity in Children Under 12

Childhood obesity affects millions of U.S. children and adolescents. [6] The American Academy of Pediatrics' 2023 guideline recommends pharmacotherapy for adolescents 12 and older and says clinicians may offer children ages 8 to 11 weight-loss medication according to each medication's indication, risks, and benefits, as an adjunct to intensive behavioral treatment. It also states that evidence was insufficient for a formal recommendation for obesity pharmacotherapy under age 12. Rybelsus has no pediatric or obesity indication. [7]

Pharmacokinetics of Oral Semaglutide: Adult Data and Pediatric Unknowns

In adults, oral semaglutide 14 mg achieves a mean peak plasma concentration (Cmax) of approximately 12 nmol/L with high intra-individual variability (coefficient of variation roughly 89%). [8] Absolute bioavailability averages only about 1%, compared to approximately 89% for subcutaneous semaglutide. [8] That narrow and variable absorption window means small physiologic differences can produce clinically meaningful changes in drug exposure.

SNAC Dependency and Gastric pH

SNAC raises local gastric pH transiently, protecting semaglutide from proteolytic degradation long enough for absorption across the gastric epithelium. [3] Pediatric gastric acid secretion per kilogram of body weight is higher relative to adults in some age bands, and basal gastric pH fluctuates more in younger children. These factors could reduce SNAC efficacy, though no published data confirm this in children under 12. [9]

No Evidence-Based Pediatric Dose

The adult Rybelsus schedule starts at 3 mg daily, a dose the FDA label says is not effective for glycemic control, before escalation to 7 mg and possibly 14 mg. The label provides no weight-based pediatric conversion. Milligrams per kilogram cannot substitute for pediatric pharmacokinetic data because oral semaglutide absorption is low, variable, and dependent on the tablet's SNAC formulation. [1, 8] No published source supports adapting the adult schedule for a child under 12.

Injectable vs. Oral Semaglutide in Pediatric Populations: What the Trials Show

The only pediatric semaglutide trial with publicly reported results used the subcutaneous formulation (Ozempic/Wegovy), not oral Rybelsus. The STEP TEENS trial (NCT04102189, N=201, ages 12-17) demonstrated that weekly subcutaneous semaglutide 2.4 mg produced a mean BMI reduction of 16.1% from baseline over 68 weeks, versus a 0.6% increase in the placebo group (P<0.001). [10] The New England Journal of Medicine published these results in 2022. [10]

What SCALE Kids Actually Studied

SCALE Kids was NCT04775082, not NCT05063656, and it tested once-daily subcutaneous liraglutide in children ages 6 to under 12. Its randomized results were published in the New England Journal of Medicine in 2025. [11] NCT05063656 is an unrelated gabapentin study in adolescents with autism. SCALE Kids therefore provides under-12 evidence for a different GLP-1 drug and cannot be presented as semaglutide or Rybelsus evidence.

The Oral Formulation Gap

NCT04596631 randomized 132 patients ages 10 to 17 with type 2 diabetes to oral semaglutide or placebo in addition to metformin and/or basal insulin. The study completed on February 3, 2026, but ClinicalTrials.gov lists no posted results and no peer-reviewed results were located as of August 2, 2026. [12] The trial includes some children under 12, so the earlier claim that this population was completely unstudied was wrong; the accurate conclusion is that outcome data are not yet public.

Safety Signals Relevant to the Pediatric Population

The current label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation among the most common adverse reactions in adults. It also warns about acute kidney injury from volume depletion and severe gastrointestinal reactions. [1] How often these events would occur in children under 12, and how they would affect growth or nutrition, has not been established.

Thyroid C-Cell Concerns

Semaglutide carries an FDA boxed warning for thyroid C-cell tumors based on rodent findings. The relevance to humans is unknown. The current label contraindicates Rybelsus in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and states that routine serum calcitonin or thyroid-ultrasound monitoring is of uncertain value for early detection. [1]

Growth and Development

No published data assess oral semaglutide's effects on linear growth, bone density, body composition, or pubertal progression in children under 12. STEP TEENS and the ongoing under-12 injectable trial cannot answer formulation-specific questions about Rybelsus. [10, 18]

Pancreatitis Risk

Acute pancreatitis has been reported with GLP-1 receptor agonists, and the current Rybelsus label instructs clinicians to stop the drug if pancreatitis is suspected. [1] SUSTAIN-6 provides adult injectable-semaglutide safety data, not pediatric oral-semaglutide evidence. [13]

Current Guideline Recommendations for Pediatric Weight and Diabetes Management

ADA 2026 Standards of Care

The ADA's 2026 Standards of Care recommends metformin for asymptomatic youth with type 2 diabetes and A1C below 8.5%, insulin for marked hyperglycemia or acidosis, and a GLP-1 receptor agonist and/or SGLT2 inhibitor of an approved pediatric age when goals are not met. Rybelsus is not approved for a pediatric age. [5]

AAP 2023 Obesity Guideline

The American Academy of Pediatrics obesity guideline keeps intensive health behavior and lifestyle treatment as the foundation and allows medication for ages 8 to 11 only according to a drug's indication, risks, and benefits. The guideline found insufficient evidence for a formal under-12 pharmacotherapy recommendation; it does not establish an off-label Rybelsus protocol. [7]

Endocrine Society Guidance

The Endocrine Society's Clinical Practice Guideline on obesity pharmacotherapy does not include specific recommendations for oral semaglutide in children under 12. The society recommends individualized assessment by a pediatric endocrinologist when considering off-label agents. [15]

When Might a Specialist Consider Off-Label Oral Semaglutide in a Child Under 12?

Published evidence does not currently define when benefit would outweigh risk, how to dose Rybelsus, or how to monitor it in a child under 12. The completed trial may change that assessment when results become public, but its registry entry alone cannot support prescribing claims. [12]

A useful evidence-review framework for a family and pediatric endocrinology team includes these questions:

1. What approved treatment options match the child's actual indication and age?
2. Is the goal treatment of type 2 diabetes, obesity, or both, and what evidence supports each goal?
3. What is known from NCT04596631, and are results now publicly available?
4. What uncertainties remain around dose, absorption, growth, gastrointestinal tolerability, hypoglycemia with other diabetes drugs, and long-term safety?
5. Would an appropriate clinical trial or a treatment with pediatric approval provide a better-supported option?

This framework intentionally does not invent a pediatric dose or monitoring schedule. No evidence-backed Rybelsus protocol for children under 12 is currently available.

What Families and Referring Physicians Should Know

Primary care physicians and families asking about Rybelsus for a child under 12 should understand a few concrete points.

Rybelsus is not approved for any person under 18. A pediatric endocrinology review can address the child's diagnosis, approved alternatives, and the absence of an evidence-based Rybelsus dose without implying that the completed trial has already established benefit. [1, 12]

The fasting requirement is a practical barrier. Rybelsus must be taken upon waking, with up to 4 oz of plain water, followed by at least 30 minutes before food, beverages, or other oral medications. The feasibility and exposure effects of this routine have not been studied in children under 12. [1, 8]

Injectable semaglutide has strong randomized evidence in adolescents ages 12 to 17 from STEP TEENS, and Wegovy is approved for chronic weight management in adolescents 12 and older. [10, 14] A separate study, NCT05726227, includes children ages 6 to under 12 but remains active and has no posted results. [18] Those injectable studies do not establish an oral Rybelsus dose.

Coverage for off-label pediatric use varies by plan and indication. A plan-specific formulary or authorization policy is the appropriate source; no universal approval or denial rule can be inferred from the clinical evidence reviewed here.

Ongoing Research and the Near-Term Evidence Horizon

Two studies now define the near-term evidence horizon. NCT04596631 completed its oral-semaglutide study in ages 10 to 17 in February 2026 but has not posted results. [12] NCT05726227 is studying weekly injectable semaglutide in participants ages 6 to 17 and estimates completion in December 2026. [18]

Whether an oral semaglutide pediatric trial will follow is speculative. The development pathway for oral formulations in young children is complicated by tablet-swallowing ability, SNAC-related gastric physiology concerns, and the difficulty of conducting bioequivalence studies in very young populations. [3]

Liraglutide injection (Saxenda) carries an FDA approval for chronic weight management in children age 12 and older, backed by the SCALE Teens trial. [16] SCALE Kids adds randomized liraglutide evidence below age 12, but the published paper states that no medication was approved for nonsyndromic obesity under age 12 at the time of the trial. [11]

The TODAY2 follow-up study tracked participants from the original TODAY trial into young adulthood and found that diabetes complications accumulated steadily and affected most participants by young adulthood. [17] These outcomes underscore the need for better pediatric evidence; they do not validate an untested oral-semaglutide regimen.